Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Misses Expectations By $0.11 EPS

Dianthus Therapeutics (NASDAQ:DNTH) released its quarterly earnings data on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11), Zacks reports. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%.

Dianthus Therapeutics Stock Up 8.2%

NASDAQ:DNTH traded up $2.77 during trading hours on Thursday, hitting $36.50. 214,932 shares of the stock were exchanged, compared to its average volume of 429,543. The company’s 50 day moving average is $34.16 and its two-hundred day moving average is $24.87. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $40.16. The company has a market capitalization of $1.17 billion, a P/E ratio of -11.19 and a beta of 1.56.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Dianthus Therapeutics by 77.0% during the 2nd quarter. Bank of America Corp DE now owns 165,125 shares of the company’s stock valued at $3,076,000 after acquiring an additional 71,838 shares during the last quarter. Hudson Bay Capital Management LP increased its position in shares of Dianthus Therapeutics by 53.9% in the 2nd quarter. Hudson Bay Capital Management LP now owns 115,425 shares of the company’s stock valued at $2,150,000 after buying an additional 40,425 shares in the last quarter. Rafferty Asset Management LLC increased its position in shares of Dianthus Therapeutics by 19.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company’s stock valued at $531,000 after buying an additional 4,650 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in Dianthus Therapeutics in the 3rd quarter worth $231,000. Finally, BNP Paribas Financial Markets boosted its stake in Dianthus Therapeutics by 3,547.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 49,531 shares of the company’s stock worth $923,000 after purchasing an additional 48,173 shares during the period. Institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Raymond James Financial restated an “outperform” rating and set a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Guggenheim boosted their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Wedbush boosted their price target on Dianthus Therapeutics from $44.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday. Stifel Nicolaus boosted their price target on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Robert W. Baird boosted their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, September 9th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $61.13.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.